Kotajima L, Aotsuka S, Fujimani M, Okawa-Takatsuji M, Kinoshita M, Sumiya M, Obata K
Division of Clinical Immunology, Clinical Research Institute, Tokyo, Japan.
Clin Exp Rheumatol. 1998 Jul-Aug;16(4):409-15.
To determine the matrix metalloproteinase-3 (MMP-3) levels in sera from patients with systemic lupus erythematosus (SLE) and to analyse the relationships between MMP-3 and clinical and laboratory features.
Serum MMP-3 levels were measured by an enzyme immunoassay in 124 patients with SLE and 237 patients with other systemic rheumatic diseases.
The frequencies of patients with high MMP-3 levels were 76% in SLE and 82% in rheumatoid arthritis (RA). The level of MMP-3 in the SLE patients was 193.0 +/- 171.5 ng/ml (mean +/- SD) and was almost equal to the level in the RA patients (259.5 +/- 255.6 ng/ml). The MMP-3 levels were significantly higher in SLE patients who had a history of the following abnormalities: persistent proteinuria, cellular casts, anti-double stranded DNA antibodies, decreased C3, decreased creatinine clearance (p < 0.001), circulating immune complex (p < 0.01), malar rash, hypoalbuminemia, or decreased C4 (p < 0.05). The serum MMP-3 level in patients with SLE at admission showed direct correlations with serum uric acid, total cholesterol (p < 0.001), triglyceride, the white blood cell count, and the neutrophil count (p < 0.05), as well as inverse correlations with the total protein (p < 0.01), and IgG (p < 0.05). In SLE patients with active renal disease, the median MMP-3 level at admission and that at 6 months after admission were significantly higher than that at 6 months before admission.
The increased level of serum MMP-3 in SLE is closely associated with clinical features relevant to lupus nephritis, suggesting that it plays a role in the pathogenesis of this condition.
测定系统性红斑狼疮（SLE）患者血清中基质金属蛋白酶-3（MMP-3）水平，并分析MMP-3与临床及实验室特征之间的关系。
采用酶免疫分析法检测124例SLE患者和237例其他系统性风湿性疾病患者的血清MMP-3水平。
MMP-高3水平患者的比例在SLE患者中为76%，在类风湿关节炎（RA）患者中为82%。SLE患者的MMP-3水平为193.0±171.5 ng/ml（均值±标准差），几乎与RA患者的水平（259.5±255.6 ng/ml）相等。有以下异常病史的SLE患者的MMP-3水平显著更高：持续性蛋白尿、细胞管型、抗双链DNA抗体、C3降低、肌酐清除率降低（p<0.001）、循环免疫复合物（p<0.01）、颧部红斑、低白蛋白血症或C4降低（p<0.05）。SLE患者入院时的血清MMP-3水平与血清尿酸、总胆固醇（p<0.001）、甘油三酯、白细胞计数和中性粒细胞计数（p<0.05）呈正相关，与总蛋白（p<0.01）和IgG（p<0.05）呈负相关。在有活动性肾脏疾病的SLE患者中，入院时和入院后6个月时的MMP-水平中位数显著高于入院前6个月时的水平。
SLE患者血清MMP-3水平升高与狼疮性肾炎相关的临床特征密切相关，提示其在该病的发病机制中起作用。
